Welcome to our dedicated page for RAPID MICRO BIOSYSTEMS SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
Rapid Micro Biosystems, Inc. entered an underwriting agreement for an underwritten offering of 3,581,000 Class A common shares with accompanying Series A and Series B common stock warrants, plus up to 1,463,000 pre-funded warrants with accompanying warrants. The company estimates net proceeds of about $8.9 million, to be used for working capital and general corporate purposes.
The warrants have exercise prices of $1.955 and $2.340 per share, with Series A warrants expiring one year after becoming exercisable and Series B warrants expiring five years after becoming exercisable. A concurrent registered direct offering with directors and officers covers 71,607 shares with matching warrant terms for approximately $140,000 in gross proceeds and is contingent on closing of the main offering.
Rapid Micro Biosystems, Inc. is offering 71,607 shares of Class A common stock, each sold together with a Series A warrant (exercise price $1.955) and a Series B warrant (exercise price $2.34), at a combined price of $1.955 per share, subject to consummation of, the Underwritten Offering. The company expects net proceeds of approximately $140,000, with the offering expected to close on or about May 20, 2026. Certain directors and officers have agreed to purchase an aggregate of approximately $140,000 in this offering. The prospectus supplement discloses exercise windows, expiration terms for the Series A and Series B warrants, and pro forma shares outstanding of 44,920,118 Class A shares assuming no warrant exercises, based on March 31, 2026 balances.
Rapid Micro Biosystems is offering 3,581,000 shares of Class A common stock together with accompanying Series A and Series B warrants and pre-funded warrants to certain investors under a prospectus supplement dated May 18, 2026. The offering also includes pre-funded warrants to purchase 1,463,000 shares and accompanying warrants.
The combined public offering price is $1.955 per share (and $1.945 per pre-funded warrant), with the company expecting to receive approximately $8.9 million in net proceeds after underwriting discounts and estimated offering expenses. The prospectus supplement states Series A warrants (exercise price $1.955) are exercisable six months after issuance and expire one year after issuance; Series B warrants (exercise price $2.34) are exercisable six months after issuance and expire five years after issuance.
Rapid Micro Biosystems, Inc. Schedule 13G/A Amendment No. 2 discloses that certain Longitude entities and two affiliated individuals report shared beneficial ownership of 3,529,245 shares of Class A common stock, representing 8.6% of the class. The filing cites March 31, 2026 as the share count reference, with 41,267,511 shares outstanding reported in the issuer's proxy statement.
The reporting persons named include Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., and individuals Patrick G. Enright and Juliet Tammenoms Bakker. The filing states these shares are held of record by LVPII and that LCPII, as general partner, and the two managing members may be deemed to share voting and dispositive power.
Rapid Micro Biosystems, Inc. reported Q1 2026 revenue of $8.0 million, up modestly from $7.2 million a year earlier, driven by higher product revenue. Service revenue declined slightly.
The company posted a net loss of $14.3 million (loss of $0.31 per share), widening from a $11.3 million loss in Q1 2025, as operating expenses rose to $14.2 million, led by higher general and administrative and sales and marketing costs. Operating cash outflow was $15.1 million, and total stockholders’ equity fell to $20.4 million from $33.2 million at year-end 2025.
Cash, cash equivalents and short-term investments totaled about $22.9 million as of March 31, 2026, alongside a $20.0 million term loan under a facility of up to $45.0 million. Management believes existing cash, investments and expected borrowing capacity will fund operations and capital needs for at least twelve months.
Rapid Micro Biosystems reported first quarter 2026 revenue of $8.0 million, up 11.1% from $7.2 million a year earlier, driven by 36% growth in product revenue to $5.6 million and 27.7% growth in recurring revenue to $5.1 million. The company placed six new Growth Direct systems versus three in the prior-year quarter, but service revenue declined 21.9% to $2.4 million due to lower validation activity. Gross margin was 4.6% on cost of revenue of $7.6 million, while operating expenses rose 17.9% to $14.2 million, leading to a wider net loss of $14.3 million, or $0.31 per share, compared with a $11.3 million loss, or $0.26 per share, in 2025. Cash, cash equivalents, short-term investments, and restricted cash fell to $23.2 million at March 31, 2026, from $38.6 million at year-end 2025. The company reaffirmed full-year 2026 guidance for total revenue of $37.0 million to $41.0 million, gross margin of about 20%, and 30 to 38 Growth Direct system placements.
Rapid Micro Biosystems, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on May 21, 2026. The agenda includes electing Richard Kollender as a Class II director through the 2029 annual meeting and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
The meeting will be held online via webcast, with voting available electronically before and during the event for holders of Class A common stock as of March 31, 2026, when 41,267,511 shares were outstanding. The proxy also details board structure, governance practices, director pay and 2025 executive compensation, including salary, equity awards and performance-based cash bonuses.
Rapid Micro Biosystems, Inc. announced that Chief Operating Officer John Wilson will depart effective April 10, 2026 to spend more time with his family, with no disagreement related to company operations or policies cited.
President and CEO Robert Spignesi will also serve as principal operating officer from that date, with no new material compensation arrangements. The company and Mr. Wilson entered into a Consulting Services and Separation Agreement on March 26, 2026, under which he will provide advisory services as a consultant at $200 per hour, up to 20 hours per month, through no later than June 30, 2026. The agreement extends the period to exercise his vested stock options through March 31, 2027 and places weekly limits on how many underlying Class A common shares he may dispose of, and includes customary release, confidentiality, cooperation and non‑disparagement terms.
RAPID MICRO BIOSYSTEMS, INC. chief operating officer John J. Addington reported an automatic sale of 9,603 shares of Class A common stock at an average price of $4.3181 per share. The shares were sold to cover tax obligations arising from the vesting of restricted stock units, according to the footnote.
After this transaction, he directly holds 316,762 shares of Class A common stock, indicating the sale represents a small portion of his overall position and is tied to routine equity-compensation tax withholding rather than discretionary selling.